Schedule I at Fifty-Five: The Science vs. the Scheduling

“LSD has been Schedule I for fifty-five years. Zero documented deaths from overdose toxicity in eighty years of use. The WHO's 2019 Critical Review found no evidence supporting its current scheduling level (Source not found; under review).”

LSD has been Schedule I since the Comprehensive Drug Abuse Prevention and Control Act of 1970. Schedule I requires high abuse potential, no accepted medical use, and lack of accepted safety under medical supervision. These criteria have been disputed for fifty-five years.

The safety evidence: the 2016 Global Drug Survey (30,000+ drug users) found LSD had the lowest emergency medical treatment rate of any substance surveyed, lower than alcohol, cannabis, cocaine, and MDMA. Zero deaths from LSD overdose toxicity have been documented in eighty years of human use.

The WHO Expert Committee on Drug Dependence conducted a Critical Review of LSD in 2019 and found no evidence supporting the substance's current international scheduling level (Source not found; under review). The recommendation did not change the scheduling.

The FDA's Breakthrough Therapy Designation for psilocybin (2018) effectively acknowledged that classical psychedelics may have accepted medical use. The drug company's application for synthetic psilocybin, targeted Q4 2026, will be the first formal clinical approval application.

LSD is in Phase 2 clinical trials in Switzerland, Canada, and the UK. The regulatory pathway for LSD lags psilocybin by approximately five years for commercial rather than pharmacological reasons: no company has invested the Phase 3 infrastructure for LSD that industry built for psilocybin. Hofmann proposed rescheduling in 1979. The current regulatory environment is approximately five years from implementing the proposal he always required.

Sources

• Global Drug Survey (2016)
• WHO ECDD Critical Review LSD (2019) [Source not found; under review]
• Controlled Substances Act (1970)
• Hofmann LSD My Problem Child (1979)